TDOC Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

9.680

Open

9.450

VWAP

9.48

Vol

4.97M

Mkt Cap

1.72B

Low

9.235

Amount

47.09M

EV/EBITDA(TTM)

9.10

Total Shares

180.51M

1.92B

EV/OCF(TTM)

6.67

P/S(TTM)

0.66

Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.

Events Timeline

(ET)

2026-05-28

11:20:00

BofA Bullish on Teladoc's Partnership with Walmart

2026-05-28

09:10:00

Teladoc Up 5% to $6.93 After Walmart Better Care Services Pact

2026-05-28

09:10:00

Teladoc Health Partners with Walmart to Offer Services

2026-05-14 (ET)

2026-05-14

09:20:00

BetterHelp Partners with Institute of Patient Safety and Quality of Virtual Care

News

8.5

07-07NASDAQ.COM

Investment Choices: Hims & Hers vs. Teladoc

6.5

07-07Fool

Investment Comparison Between Hims & Hers and Teladoc

8.0

07-06NASDAQ.COM

Surge in Options Volume for ANI and Teladoc

5.0

07-03Newsfilter

Teladoc Health Grants Stock Award to New Employee

9.5

07-02Fool

Teladoc Health Shares Surge 28% Amid Recovery Efforts

9.5

07-02NASDAQ.COM

Teladoc's Business Shows Improvement Amid Challenges

15 Analyst Rating

Wall Street analysts forecast TDOC stock price to rise

3 Buy

12 Hold

0 Sell

Hold

Current: 0.000

Low

7.50

Averages

8.91

High

12.00

Current: 0.000

Low

7.50

Averages

8.91

High

12.00

BofA

Buy

maintain

AI Analysis

2026-07-07

New

Reason

BofA

Price Target

AI Analysis

2026-07-07

New

maintain

Buy

Reason

BofA raised the firm's price target on Teladoc to $10.50 from $9 and keeps a Buy rating on the shares. June Sensor Tower data suggests BetterHelp user engagement may be stabilizing after more than a year of declines, with monthly active users returning to year-over-year growth in June, driven primarily by the U.S., the analyst tells investors in a research note.

Goldman Sachs

Buy

maintain

$7 -> $8

2026-05-27

Reason

Goldman Sachs

Price Target

$7 -> $8

2026-05-27

maintain

Buy

Reason

Goldman Sachs raised the firm's price target on Teladoc to $8 from $7 and keeps a Buy rating on the shares. MedTech has experienced one of its weakest periods in 15-20 years across performance, valuation, and outlook revisions, pressured by sector rotation, slower growth, reimbursement and competitive risks, and aging investment narratives, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TDOC

Unlock Now

Valuation Metrics

The current forward P/E ratio for Teladoc Health Inc (TDOC.N) is 303.03, compared to its 5-year average forward P/E of 11.22. For a more detailed relative valuation and DCF analysis to assess Teladoc Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

11.22

Current PE

303.03

Overvalued PE

113.56

Undervalued PE

-91.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

18.80

Current EV/EBITDA

11.60

Overvalued EV/EBITDA

38.19

Undervalued EV/EBITDA

-0.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.06

Current PS

0.66

Overvalued PS

4.62

Undervalued PS

-0.50

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best swing trades

Intellectia · 40 candidates

Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: $5.00 - $18.00One Week Rise Prob: >= 70Monthly Average Dollar Volume: >= 1,500,000

Ticker

Name

Market Cap$

TALK

Talkspace Inc

856.44M

ACRS

Aclaris Therapeutics Inc

435.91M

PHIO

Phio Pharmaceuticals Corp

14.64M

WTI

W&T Offshore Inc

424.02M

TURB

Turbo Energy SA

41.20M

OLN

Olin Corp

2.70B

what are some day trades i can do with 300$

Intellectia · 122 candidates

Region: USPrice: $1.00 - $30.00Price Change Pct: $3.00 - $100.00Relative Vol: >= 1.50Beta: HighRiskList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

UWMC

UWM Holdings Corp

6.66B

PATH

UiPath Inc

5.32B

AAL

American Airlines Group Inc

8.80B

OPEN

Opendoor Technologies Inc

4.77B

RGTI

Rigetti Computing Inc

5.82B

LUNR

Intuitive Machines Inc

3.23B

Whales Holding TDOC

Tang Capital Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Teladoc Health Inc (TDOC) stock price today?

The current price of TDOC is 9.52 USD — it has increased 2.48

What is Teladoc Health Inc (TDOC)'s business?

What is the price predicton of TDOC Stock?

Wall Street analysts forecast TDOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TDOC is8.91 USD with a low forecast of 7.50 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.